Improvement of glycemic control in adults with type 2 diabetes mellitus
Who takes it
Adults
Adult dose
The dose of this drug for antidiabetic therapy should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: empagliflozin 25mg and metformin hydrochloride extended-release 2000 mg.
This drug should be taken once daily with the evening meal to reduce gastrointestinal adverse reactions caused by metformin. To reduce gastrointestinal adverse reactions associated with metformin use, the dose of metformin hydrochloride should be increased gradually.
Patients taking this drug 10/1000 mg extended-release tablets or 25/1000 mg extended-release tablets should take 1 tablet once daily.
Patients taking this drug 5/1000 mg extended-release tablets or 12.5/1000 mg extended-release tablets should take 2 tablets at the same time once daily.
To maintain the extended-release properties, this drug should be swallowed whole and not split, crushed, ground, or chewed. This drug may not dissolve completely and may be excreted in the stool. It is not known whether the material excreted in the stool contains the active ingredients of the drug. If a patient repeatedly reports finding this drug in the stool, healthcare professionals should assess whether blood glucose is being adequately controlled (see Precautions, 5. General Precautions).
For patients whose blood glucose is not adequately controlled with metformin alone or in combination with other drugs such as insulin, the recommended initial total daily dose when taking this drug is empagliflozin 10 mg and the patient's current metformin dose. If empagliflozin 10 mg is well tolerated and additional glycemic control is needed, the dose may be increased to empagliflozin 25 mg.
Patients switching from combination therapy with empagliflozin and metformin to this drug should receive their current doses of empagliflozin and metformin.
When switching from immediate-release metformin to an extended-release formulation, glycemic control should be closely monitored and dosage adjustments made as appropriate.
When this drug is coadministered with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia (see Precautions, 4. Adverse Reactions and 6. Interactions).
Special Populations
Renal Impairment
Because dose adjustment may be required based on renal function, assessment of renal function is recommended before starting this drug and periodically during treatment.
No dosage adjustment of this drug is necessary in patients with mild renal impairment [creatinine clearance (CrCl) ≧ 60 mL/min or estimated glomerular filtration rate (eGFR) ≧ 60 mL/min/1.73 m2].
In patients with moderate renal impairment [CKD stage 3A, creatinine clearance (CrCl) ≧ 45 mL/min and <60mL/min or estimated glomerular filtration rate (eGFR) ≧ 45 mL/min/1.73m2 and <60 mL/min/1.73m2] who tolerate treatment well and have no other conditions that may increase the risk of lactic acidosis, this drug may be used with adjustment of the metformin hydrochloride dose as follows:
- Since the starting dose of extended-release metformin hydrochloride is 500 mg or 750 mg once daily, treatment should not be initiated with this drug. The maximum daily dose of metformin hydrochloride is 1000 mg.
If creatinine clearance (CrCl) decreases to <45 ml/min or estimated glomerular filtration rate (eGFR) decreases to <45 ml/min/1.73m2, this drug should be discontinued immediately.
Elderly Patients
For patients aged 75 years and older, renal function and the risk of volume depletion should be considered.
Improvement of glycemic control in adults with type 2 diabetes mellitus
Blood glucose control issues in adults with Type 2 diabetes
cardiovascular disease
View approved original textHide original text
This medication helps improve blood glucose control in adults with Type 2 diabetes by using a combination of Empagliflozin and Metformin. It particularly acts as a complement to dietary and exercise therapies. Additionally, it is considered for use in patients with Type 2 diabetes who have accompanying cardiovascular disease, taking into account its effect on the occurrence of cardiovascular events. Therefore, this medication effectively enhances the treatment and blood glucose management of Type 2 diabetes.
How to take
Adult dose
The dose of this drug for antidiabetic therapy should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: empagliflozin 25mg and metformin hydrochloride extended-release 2000 mg.
This drug should be taken once daily with the evening meal to reduce gastrointestinal adverse reactions caused by metformin. To reduce gastrointestinal adverse reactions associated with metformin use, the dose of metformin hydrochloride should be increased gradually.
Patients taking this drug 10/1000 mg extended-release tablets or 25/1000 mg extended-release tablets should take 1 tablet once daily.
Patients taking this drug 5/1000 mg extended-release tablets or 12.5/1000 mg extended-release tablets should take 2 tablets at the same time once daily.
To maintain the extended-release properties, this drug should be swallowed whole and not split, crushed, ground, or chewed. This drug may not dissolve completely and may be excreted in the stool. It is not known whether the material excreted in the stool contains the active ingredients of the drug. If a patient repeatedly reports finding this drug in the stool, healthcare professionals should assess whether blood glucose is being adequately controlled (see Precautions, 5. General Precautions).
For patients whose blood glucose is not adequately controlled with metformin alone or in combination with other drugs such as insulin, the recommended initial total daily dose when taking this drug is empagliflozin 10 mg and the patient's current metformin dose. If empagliflozin 10 mg is well tolerated and additional glycemic control is needed, the dose may be increased to empagliflozin 25 mg.
Patients switching from combination therapy with empagliflozin and metformin to this drug should receive their current doses of empagliflozin and metformin.
When switching from immediate-release metformin to an extended-release formulation, glycemic control should be closely monitored and dosage adjustments made as appropriate.
When this drug is coadministered with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia (see Precautions, 4. Adverse Reactions and 6. Interactions).
Special Populations
Renal Impairment
Because dose adjustment may be required based on renal function, assessment of renal function is recommended before starting this drug and periodically during treatment.
No dosage adjustment of this drug is necessary in patients with mild renal impairment [creatinine clearance (CrCl) ≧ 60 mL/min or estimated glomerular filtration rate (eGFR) ≧ 60 mL/min/1.73 m2].
In patients with moderate renal impairment [CKD stage 3A, creatinine clearance (CrCl) ≧ 45 mL/min and <60mL/min or estimated glomerular filtration rate (eGFR) ≧ 45 mL/min/1.73m2 and <60 mL/min/1.73m2] who tolerate treatment well and have no other conditions that may increase the risk of lactic acidosis, this drug may be used with adjustment of the metformin hydrochloride dose as follows:
- Since the starting dose of extended-release metformin hydrochloride is 500 mg or 750 mg once daily, treatment should not be initiated with this drug. The maximum daily dose of metformin hydrochloride is 1000 mg.
If creatinine clearance (CrCl) decreases to <45 ml/min or estimated glomerular filtration rate (eGFR) decreases to <45 ml/min/1.73m2, this drug should be discontinued immediately.
Elderly Patients
For patients aged 75 years and older, renal function and the risk of volume depletion should be considered.
Precautions
This medication is used for the treatment of diabetes and helps lower blood glucose levels.
However, certain precautions must be strictly followed when taking this medication.
First, one of the ingredients, Metformin, can rarely cause a serious condition called lactic acidosis, which can be life-threatening, requiring utmost caution.
Also, when taken with insulin or other diabetes medications, symptoms of hypoglycemia may occur, so blood glucose levels should be monitored closely.
This medication should not be administered to patients with significantly decreased kidney function or severe liver dysfunction, and should be avoided in cases of acute infections, dehydration, or serious heart problems.
Particularly, patients scheduled for surgery should discontinue this medication 48 hours prior to surgery and resume only after kidney function returns to normal.
This medication may increase the risk of genital or urinary infections; therefore, if infection symptoms appear, prompt consultation with a physician is advised.
During treatment, regular checks of serum creatinine levels are essential to monitor kidney function.
Additionally, this medication may reduce Vitamin B12 levels; hence, periodic checks of Vitamin B12 levels are recommended for long-term use.
Women who are pregnant or breastfeeding should avoid taking this medication, and women of childbearing potential should consult a physician before taking it.
Elderly patients or those at risk of fluid loss should be cautious to avoid dehydration or hypotension, and adequate fluid intake is necessary during treatment.
It is advisable to avoid excessive drinking or alcohol consumption while taking this medication.
When taking the tablets, do not crush or chew them; swallow them whole, and it is normal for the tablet coating to appear in the stool.
Lastly, if any adverse reactions are suspected or symptoms worsen while taking this medication, notify healthcare professionals immediately.
Side effects
Severe lactic acidosis
severe hypoglycemia
hypoglycemia
urinary tract infection
genital infection
increased urination
decreased and deficient vitamin B12
ketoacidosis
lactic acidosis
decreased fluid volume
Show 176 moreCollapse
nausea
vomiting
diarrhea
abdominal pain
loss of appetite
constipation
abnormal liver function tests
hepatitis
taste disturbance
itching
rash
urticaria
erythema
angioedema
dysuria
interstitial nephritis
thirst
increased serum lipids
increased blood creatinine
decreased glomerular filtration rate
vaginal molluscum contagiosum
vulvitis
balanitis
perineal necrosis
increased blood creatinine
decreased glomerular filtration rate
gastrointestinal symptoms
chronic gastritis
various neurological disorders
cerebral infarction
soft tissue infection
pneumonia
ankle fracture
epicondylitis
facial bone fracture
musculoskeletal pain
myocardial infarction
pancreatic carcinoma
diarrhea
nausea
gastric ulcer
colitis
vomiting
ischemic colitis
intestinal bleeding
appendiceal abscess
appendicitis
meningitis
chronic otitis media
peritonsillar abscess
pulmonary tuberculosis
sepsis
subcutaneous abscess
tubo-ovarian abscess
vestibular neuritis
headache
positional vertigo
amnesia
carotid artery stenosis
diabetic neuropathy
facial paralysis
memory impairment
neuralgia
Parkinsonism
polyneuropathy
sensory impairment
drowsiness
central nervous system origin vertigo
fatigue
peripheral edema
facial edema
peripheral swelling
fever
facial swelling
chills
unusual sensations
swelling
pain
pain at the puncture site
vascular stent stenosis
vascular stent thrombosis
chest pain
weight loss
vulvar pruritus
benign prostatic hyperplasia
diabetic retinopathy
double vision
hypertension
insomnia
dizziness
unstable angina
anemia
lymphadenopathy
hypothyroidism
thyroid mass
nasopharyngitis
shingles
vulvar pruritus
genital pruritus
dyslipidemia
hyperglycemia
dermoid cysts
seborrheic dermatitis
atopic dermatitis
diabetic foot
nummular eczema
heat rash
sebaceous gland hyperplasia
lumbar spinal canal stenosis
myalgia
limb pain
musculoskeletal chest pain
arthralgia
cervical stenosis
fibromyalgia
flank pain
fracture pain
muscle weakness
osteoarthritis
osteoporosis
rotator cuff syndrome
astigmatism
cataract
allergic conjunctivitis
blurred vision
corneal abrasion
glaucoma
macular fibrosis
eye discomfort
eye congestion
pathologic myopia
retinal detachment
retinal crystals
retinal vein occlusion
serous retinal detachment
eyelid swelling
visual impairment
vitreous floaters
vitreous hemorrhage
nasal bleeding
asthma
exertional dyspnea
wet cough
allergic rhinitis
residual phlegm
cough
skin laceration
contusion
rib fracture
concussion
corneal abrasion
fall
hand fracture
iliotibial band syndrome
open ocular injury
pelvic fracture
road traffic accident
splenic injury
sternum fracture
palpitations
tachycardia
atherosclerosis
deep vein thrombosis
diabetic vascular complications
peripheral artery occlusive disease
anxiety
depression
sleep disorder
acute cholecystitis
autoimmune hepatitis
cholelithiasis
hepatitis
dysmenorrhea
positional dizziness
vertigo
angina
Not everyone experiences these, and they can vary from person to person.
Storage
Store this medication in a closed container to protect it from air and moisture. It is best kept at room temperature between 1 degree and 30 degrees.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
Questions about this medicine
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety. Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.